A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07325136 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Small Cell Lung Cancer

Interventions

DRUG: BMS-986525
DRUG: Nivolumab

Sponsor

Bristol-Myers Squibb